Infant Bacterial Therapeutics AB (publ) (ST:IBT-B) — Market Cap & Net Worth
Market Cap & Net Worth: Infant Bacterial Therapeutics AB (publ) (IBT-B)
Infant Bacterial Therapeutics AB (publ) (ST:IBT-B) has a market capitalization of $88.26 Million (Skr820.14 Million) as of June 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #19761 globally and #345 in its home market, demonstrating a 4.30% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Infant Bacterial Therapeutics AB (publ)'s stock price Skr63.00 by its total outstanding shares 13018137 (13.02 Million). Review Infant Bacterial Therapeutics AB (publ) debt and liabilities to assess the company's total debt and financial obligations.
Infant Bacterial Therapeutics AB (publ) Market Cap History: 2016 to 2026
Infant Bacterial Therapeutics AB (publ)'s market capitalization history from 2016 to 2026. Data shows growth from $55.17 Million to $88.26 Million (0.73% CAGR).
Infant Bacterial Therapeutics AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Infant Bacterial Therapeutics AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
18772.86x
Infant Bacterial Therapeutics AB (publ)'s market cap is 18772.86 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $55.17 Million | $162.00K | -$38.11 Million | 340.57x | N/A |
| 2017 | $161.11 Million | $238.00K | -$36.16 Million | 676.93x | N/A |
| 2022 | $70.05 Million | $12.00K | -$65.45 Million | 5837.33x | N/A |
| 2023 | $126.09 Million | $77.00K | -$123.07 Million | 1637.49x | N/A |
| 2024 | $75.09 Million | $4.00K | -$136.91 Million | 18772.86x | N/A |
Competitor Companies of IBT-B by Market Capitalization
Companies near Infant Bacterial Therapeutics AB (publ) in the global market cap rankings as of June 19, 2026.
Key companies related to Infant Bacterial Therapeutics AB (publ) by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
Infant Bacterial Therapeutics AB (publ) Historical Marketcap From 2016 to 2026
Between 2016 and today, Infant Bacterial Therapeutics AB (publ)'s market cap moved from $55.17 Million to $ 88.26 Million, with a yearly change of 0.73%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr88.26 Million | +24.75% |
| 2025 | Skr70.75 Million | -5.78% |
| 2024 | Skr75.09 Million | -40.44% |
| 2023 | Skr126.09 Million | +80.00% |
| 2022 | Skr70.05 Million | -25.15% |
| 2021 | Skr93.58 Million | -40.36% |
| 2020 | Skr156.91 Million | -21.68% |
| 2019 | Skr200.34 Million | +1.06% |
| 2018 | Skr198.24 Million | +23.04% |
| 2017 | Skr161.11 Million | +192.01% |
| 2016 | Skr55.17 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Infant Bacterial Therapeutics AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $88.26 Million USD |
| MoneyControl | $88.26 Million USD |
| MarketWatch | $88.26 Million USD |
| marketcap.company | $88.26 Million USD |
| Reuters | $88.26 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Infant Bacterial Therapeutics AB (publ)
Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also develop… Read more